Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study

Research output: Contribution to journalArticle

Abstract

Background: Addition of nitroglycerine (NTG) to transcatheter arterial embolization/transarterial chemoembolization (TAE/TACE) has been shown to increase deposition of Lipiodol emulsion in hepatocellular carcinoma (HCC) tumors. The aim of this retrospective study was to evaluate if the addition of nitroglycerin (NTG) to TAE/TACE improved treatment response in HCC. Methods: Patients with HCC either received (n = 42) or did not receive (non-NTG) (n = 111) NTG and an emulsion of Lipiodol with or without doxorubicin, followed by embolization with Gelfoam pledgets. Treatment response was monitored using dual-energy computer tomography (CT). Disease progression and overall survival (OS) were monitored. Results: The rate of disease progression in the NTG group was 86.5% and in the non-NTG group was 88.6%. Median time to disease progression was 12 months (95% CI; 9.0, 15.0) for the NTG group and 12 months (95% CI; 10.4, 13.6) for the non-NTG groups (P = 0.040). No difference was observed in OS between the NTG (60 months) and the non-NTG groups (41 months) (P = 0.117). Multivariate analysis found that in the NTG group, OS was associated with Cancer of the Liver Italian Program (CLIP) stage I and Barcelona Clinic Liver Cancer (BCLC) stage B. Conclusions: Addition of NTG to TAE/TACE did not result in improved OS or disease progression.

Original languageEnglish
Pages (from-to)542-552
Number of pages11
JournalClinics and Research in Hepatology and Gastroenterology
Volume42
Issue number6
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Nitroglycerin
Hepatocellular Carcinoma
Retrospective Studies
Disease Progression
Ethiodized Oil
Survival
Liver Neoplasms
Emulsions
Absorbable Gelatin Sponge
Doxorubicin
Multivariate Analysis
Tomography
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{fc6b3d4ef5474b2f8ee17e1f4f1e1efa,
title = "Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study",
abstract = "Background: Addition of nitroglycerine (NTG) to transcatheter arterial embolization/transarterial chemoembolization (TAE/TACE) has been shown to increase deposition of Lipiodol emulsion in hepatocellular carcinoma (HCC) tumors. The aim of this retrospective study was to evaluate if the addition of nitroglycerin (NTG) to TAE/TACE improved treatment response in HCC. Methods: Patients with HCC either received (n = 42) or did not receive (non-NTG) (n = 111) NTG and an emulsion of Lipiodol with or without doxorubicin, followed by embolization with Gelfoam pledgets. Treatment response was monitored using dual-energy computer tomography (CT). Disease progression and overall survival (OS) were monitored. Results: The rate of disease progression in the NTG group was 86.5{\%} and in the non-NTG group was 88.6{\%}. Median time to disease progression was 12 months (95{\%} CI; 9.0, 15.0) for the NTG group and 12 months (95{\%} CI; 10.4, 13.6) for the non-NTG groups (P = 0.040). No difference was observed in OS between the NTG (60 months) and the non-NTG groups (41 months) (P = 0.117). Multivariate analysis found that in the NTG group, OS was associated with Cancer of the Liver Italian Program (CLIP) stage I and Barcelona Clinic Liver Cancer (BCLC) stage B. Conclusions: Addition of NTG to TAE/TACE did not result in improved OS or disease progression.",
author = "Yi-Sheng Liu and Chia-Ying Lin and Ming-Tsung Chuang and Yi-Shan Tsai and Chien-Kuo Wang and Ming-Ching Ou",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.clinre.2018.04.009",
language = "English",
volume = "42",
pages = "542--552",
journal = "Clinics and Research in Hepatology and Gastroenterology",
issn = "2210-7401",
publisher = "Elsevier Masson",
number = "6",

}

TY - JOUR

T1 - Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma

T2 - Five-year retrospective study

AU - Liu, Yi-Sheng

AU - Lin, Chia-Ying

AU - Chuang, Ming-Tsung

AU - Tsai, Yi-Shan

AU - Wang, Chien-Kuo

AU - Ou, Ming-Ching

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Addition of nitroglycerine (NTG) to transcatheter arterial embolization/transarterial chemoembolization (TAE/TACE) has been shown to increase deposition of Lipiodol emulsion in hepatocellular carcinoma (HCC) tumors. The aim of this retrospective study was to evaluate if the addition of nitroglycerin (NTG) to TAE/TACE improved treatment response in HCC. Methods: Patients with HCC either received (n = 42) or did not receive (non-NTG) (n = 111) NTG and an emulsion of Lipiodol with or without doxorubicin, followed by embolization with Gelfoam pledgets. Treatment response was monitored using dual-energy computer tomography (CT). Disease progression and overall survival (OS) were monitored. Results: The rate of disease progression in the NTG group was 86.5% and in the non-NTG group was 88.6%. Median time to disease progression was 12 months (95% CI; 9.0, 15.0) for the NTG group and 12 months (95% CI; 10.4, 13.6) for the non-NTG groups (P = 0.040). No difference was observed in OS between the NTG (60 months) and the non-NTG groups (41 months) (P = 0.117). Multivariate analysis found that in the NTG group, OS was associated with Cancer of the Liver Italian Program (CLIP) stage I and Barcelona Clinic Liver Cancer (BCLC) stage B. Conclusions: Addition of NTG to TAE/TACE did not result in improved OS or disease progression.

AB - Background: Addition of nitroglycerine (NTG) to transcatheter arterial embolization/transarterial chemoembolization (TAE/TACE) has been shown to increase deposition of Lipiodol emulsion in hepatocellular carcinoma (HCC) tumors. The aim of this retrospective study was to evaluate if the addition of nitroglycerin (NTG) to TAE/TACE improved treatment response in HCC. Methods: Patients with HCC either received (n = 42) or did not receive (non-NTG) (n = 111) NTG and an emulsion of Lipiodol with or without doxorubicin, followed by embolization with Gelfoam pledgets. Treatment response was monitored using dual-energy computer tomography (CT). Disease progression and overall survival (OS) were monitored. Results: The rate of disease progression in the NTG group was 86.5% and in the non-NTG group was 88.6%. Median time to disease progression was 12 months (95% CI; 9.0, 15.0) for the NTG group and 12 months (95% CI; 10.4, 13.6) for the non-NTG groups (P = 0.040). No difference was observed in OS between the NTG (60 months) and the non-NTG groups (41 months) (P = 0.117). Multivariate analysis found that in the NTG group, OS was associated with Cancer of the Liver Italian Program (CLIP) stage I and Barcelona Clinic Liver Cancer (BCLC) stage B. Conclusions: Addition of NTG to TAE/TACE did not result in improved OS or disease progression.

UR - http://www.scopus.com/inward/record.url?scp=85047647755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047647755&partnerID=8YFLogxK

U2 - 10.1016/j.clinre.2018.04.009

DO - 10.1016/j.clinre.2018.04.009

M3 - Article

C2 - 29859998

AN - SCOPUS:85047647755

VL - 42

SP - 542

EP - 552

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

SN - 2210-7401

IS - 6

ER -